2023 World Conference on Lung Cancer (Posters)-EP12.02. Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative

EP12.02. Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative - PDF(Abstract)

Back to course

Pdf Summary

This study focused on improving the personalized care for patients with advanced ALK non-small cell lung cancer (NSCLC) through a blended continuing education and quality improvement initiative. The researchers invited three community hospital-based cancer centers to participate in an 18-month long project.<br /><br />The project involved a baseline assessment of how the clinicians diagnosed and treated patients with advanced ALK NSCLC. This assessment included chart reviews, focus group discussions, and online surveys. After reviewing the baseline data, each site developed problem statements and aim statements, and implemented improvement projects. These projects included facilitated follow-up team meetings for coaching and peer learning, as well as the Plan-Do-Study-Act model. The focus was on biomarker testing and integrating shared decision-making (SDM) into treatment planning.<br /><br />During the project, clinicians also participated in a live virtual educational intervention that addressed incorporating clinical advances in ALK NSCLC treatment planning and SDM strategies. This educational activity was recorded and made available to a national audience of cancer clinicians.<br /><br />The results showed an increase in biomarker testing for all patients with stage IV NSCLC and an increase in the use of appropriate targeted therapy in patients with ALK NSCLC. Oncologists felt more confident in tailoring treatment plans after participating in the educational initiative.<br /><br />The learners in the online educational activity demonstrated an increase in knowledge regarding multigene NGS panel testing, the efficacy of ALK inhibitors in patients with CNS metastases, and treatment-related adverse effects attributed to different ALK inhibitors.<br /><br />Overall, this quality improvement initiative successfully improved molecular testing and the selection of appropriate ALK inhibitors for the treatment of ALK NSCLC. The blended model of continuing education and quality improvement proved to be effective in real-world community-based practices.

Asset Subtitle

D. Ross Camidge

Meta Tag

Speaker D. Ross Camidge

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

personalized care

ALK non-small cell lung cancer

continuing education

quality improvement

baseline assessment

improvement projects

biomarker testing

shared decision-making

educational intervention

molecular testing